NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
Updated: Feb 10
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Sponsor
Amsterdam UMC, location VUmc
Collaborator
Celgene
Location
Netherlands
ClinicalTrials.gov Identifier: NCT04392037
Official Title: A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study
First Posted : May 18, 2020
Click here for details on Clinicaltrials.gov
Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone
Location
Europe
Netherlands